Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Recombinant vectors targeting NY-ESO-1 assessed in phase II trials

May 16, 2012

L-DOS-47 begins phase I/II study for NSCLC

May 15, 2012

Biovest plans to seek European marketing approval for cancer vaccine

May 15, 2012

Mologen study meets primary endpoint

May 14, 2012

Transgene gives update on development of HPV vaccine candidate

May 10, 2012

ImmunoCellular Therapeutics advances phase II ICT-107 trial

May 10, 2012

Mayo Clinic to conduct phase I trials on HER2/Neu antigens

May 9, 2012

New phase III study of Adcetris begins

May 8, 2012

NRC discloses new single-domain monoclonal antibodies

May 4, 2012

Merck Sharp & Dohme patents novel HER3-specific antibodies

May 4, 2012

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...